Pulmonary adenocarcinomas with micropapillary component significantly correlate with recurrence, but can be well controlled with EGFR tyrosine kinase inhibitors in the early stages

Lung Cancer

Volumn 81, Issue 1, 2013, Pages 53-59

  Sumiyoshi, Shinji ^a   Yoshizawa, Akihiko ^a,b   Sonobe, Makoto ^a   Kobayashi, Masashi ^a   Fujimoto, Masakazu ^a   Tsuruyama, Tatsuaki ^a   Date, Hiroshi ^a   Haga, Hironori ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

EGFR; EGFR TKI; KRAS; Lung adenocarcinoma; Micropapillary component; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR VOLUME;

ADENOCARCINOMA, PAPILLARY; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84878998751     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.04.003     Document Type: Article

References (27)

1. Boyle P., Levin B. World cancer report 2008 2008, International Agency for Research on Cancer, Lyon.
2. Pathology and genetics: tumours of the lung, pleura, thymus and heart 2004, IARC Press, Lyon. W. Travis, E. Brambilla, H. Muller-Hermelink, C. Harris (Eds.).
3. Travis W.D., Garg K., Franklin W.A., Wistuba I.I., Sabloff B., Noguchi M., et al. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol 2005, 23:3279-3287.
4. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
5. Amin M.B., Tamboli P., Merchant S.H., Ordonez N.G., Ro J., Ayala A.G., et al. Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol 2002, 26:358-364.
6. Kamiya K., Hayashi Y., Douguchi J., Hashiguchi A., Yamada T., Izumi Y., et al. Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma. Mod Pathol 2008, 21:992-1001.
7. Kawakami T., Nabeshima K., Makimoto Y., Hamasaki M., Iwasaki A., Shirakusa T., et al. Micropapillary pattern and grade of stromal invasion in pT1 adenocarcinoma of the lung: usefulness as prognostic factors. Mod Pathol 2007, 20:514-521.
8. Makimoto Y., Nabeshima K., Iwasaki H., Miyoshi T., Enatsu S., Shiraishi T., et al. Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (
9. Miyoshi T., Satoh Y., Okumura S., Nakagawa K., Shirakusa T., Tsuchiya E., et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol 2003, 27:101-109.
10. Nagano T., Ishii G., Nagai K., Ito T., Kawase A., Takahashi K., et al. Structural and biological properties of a papillary component generating a micropapillary component in lung adenocarcinoma. Lung Cancer 2010, 67:282-289.
11. Ninomiya H., Hiramatsu M., Inamura K., Nomura K., Okui M., Miyoshi T., et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type. Lung Cancer 2009, 63:235-240.
12. Roh M.S., Lee J.I., Choi P.J., Hong Y.S. Relationship between micropapillary component and micrometastasis in the regional lymph nodes of patients with stage I lung adenocarcinoma. Histopathology 2004, 45:580-586.
13. Sanchez-Mora N., Presmanes M.C., Monroy V., Moreno N., Lara-Martinez J.M., Aladro M.H., et al. Micropapillary lung adenocarcinoma: a distinctive histologic subtype with prognostic significance. Case series. Hum Pathol 2008, 39:324-330.
14. Tsutsumida H., Nomoto M., Goto M., Kitajima S., Kubota I., Hirotsu Y., et al. A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis. Mod Pathol 2007, 20:638-647.
15. Zhang J., Liang Z., Gao J., Luo Y., Liu T. Pulmonary adenocarcinoma with a micropapillary pattern: a clinicopathological, immunophenotypic and molecular analysis. Histopathology 2011, 59:1204-1214.
16. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
17. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
18. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
19. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
20. De Oliveira Duarte Achcar R., Nikiforova M.N., Yousem S.A. Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. Am J Clin Pathol 2009, 131:694-700.
21. Motoi N., Szoke J., Riely G.J., Seshan V.E., Kris M.G., Rusch V.W., et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes. EGFR mutations and gene expression analysis. Am J Surg Pathol 2008, 32:810-827.
22. Sun P.L., Seol H., Lee H.J., Yoo S.B., Kim H., Xu X., et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes. EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 2012, 7:323-330.
23. TNM classification of malignant tumours 2009, John Wiley & Sons, New York. 7th ed. L.H. Sobin, M.K. Gospodarowicz, C. Wittekind (Eds.).
24. Sonobe M., Kobayashi M., Ishikawa M., Kikuchi R., Nakayama E., Takahashi T., et al. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas. Ann Surg Oncol 2012, 19(Suppl. 3):S347-S354.
25. Sonobe M., Manabe T., Wada H., Tanaka F. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 2005, 93:355-363.
26. Hatzaki A., Razi E., Anagnostopoulou K., Iliadis K., Kodaxis A., Papaioannou D., et al. A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients. Mol Cell Probes 2001, 15:243-247.
27. Ettinger D.S., Akerley W., Bepler G., Blum M.G., Chang A., Cheney R.T., et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2010, 8:740-801.